Browsing Molecular Pathology by author "Chisholm, Julia"
Now showing items 1-16 of 16
-
Access to clinical trials for adolescents with soft tissue sarcomas: Enrollment in European pediatric Soft tissue sarcoma Study Group (EpSSG) protocols
Ferrari, A; Trama, A; De Paoli, A; Bergeron, C; Merks, JHM; et al. (2017-06) -
Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial.
Bisogno, G; Jenney, M; Bergeron, C; Gallego Melcón, S; Ferrari, A; et al. (ELSEVIER SCIENCE INC, 2018-08-01)BACKGROUND: Rhabdomyosarcoma is an aggressive tumour that can develop in almost any part of the body. Doxorubicin is an effective drug against rhabdomyosarcoma, but its role in combination with an established multidrug ... -
Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors
Doz, F; van Tilburg, CM; Geoerger, B; Højgaard, M; Øra, I; et al.Abstract Background Larotrectinib is a first-in-class, highly selective tropomyosin receptor kinase (TRK) inhibitor approved to treat adult and pediatric patients with TRK fusion-positive cancer. The aim of this study was ... -
Is surveillance imaging in pediatric patients treated for localized rhabdomyosarcoma useful? The European experience.
Vaarwerk, B; Mallebranche, C; Affinita, MC; van der Lee, JH; Ferrari, A; et al.Background After the completion of therapy, patients with localized rhabdomyosarcoma (RMS) are subjected to intensive radiological tumor surveillance. However, the clinical benefit of this surveillance is unclear. This ... -
Local staging and treatment in extremity rhabdomyosarcoma. A report from the EpSSG-RMS2005 study.
Terwisscha van Scheltinga, SEJ; Wijnen, MHWA; Martelli, H; Rogers, T; Mandeville, H; et al.Rhabdomyosarcoma of the extremities present with two main challenges: correct evaluation of initial regional nodal involvement and define adequate local treatment. Methods Pediatric patients with localized rhabdomyosarcoma ... -
Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer.
Moreno, L; Casanova, M; Chisholm, JC; Berlanga, P; Chastagner, PB; et al. (2018-09)Background nab-Paclitaxel has demonstrated efficacy in adults with solid tumours and preclinical activity in paediatric solid tumour models. Results from phase I of a phase I/II study in paediatric patients with ... -
Randomized Phase II Trial of Vincristine-Irinotecan With or Without Temozolomide, in Children and Adults With Relapsed or Refractory Rhabdomyosarcoma: A European Paediatric Soft Tissue Sarcoma Study Group and Innovative Therapies for Children With Cancer Trial.
Defachelles, A-S; Bogart, E; Casanova, M; Merks, JHM; Bisogno, G; et al.Purpose The VIT-0910 trial was conducted to evaluate efficacy and safety of the vincristine-irinotecan combination with and without temozolomide (VIT and VI, respectively) in relapsed or refractory rhabdomyosarcoma (RMS). ... -
The Impact of Radiation Therapy in Children and Adolescents With Metastatic Rhabdomyosarcoma
Chisholm, J; Mandeville, H -
Transforming Training into Practice with the Conflict Management Framework: a Mixed Methods Study
Chisholm, J; Snowball, C -
Transforming training into practice with the conflict management framework: a mixed methods study
Lyons, O; Forbat, L; Menson, E; Chisholm, JC; Pryde, K; et al.<jats:sec><jats:title>Objective</jats:title><jats:p>To implement and evaluate the use of the conflict management framework (CMF) in four tertiary UK paediatric services.</jats:p></jats:sec><jats:sec><jats:title>Design</j ... -
Tumour-agnostic drugs in paediatric cancers.
Chisholm, JC; Carceller, F; Marshall, LVThe recognition that new cancer drugs can be truly tumour-agnostic based on mechanism-of-action is important for paediatric cancers, where access to novel targeted therapies developed for adult indications has sometimes ... -
Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial.
Bisogno, G; De Salvo, GL; Bergeron, C; Gallego Melcón, S; Merks, JH; et al. (2019-11)Background For more than three decades, standard treatment for rhabdomyosarcoma in Europe has included 6 months of chemotherapy. The European paediatric Soft tissue sarcoma Study Group (EpSSG) aimed to investigate whether ...